ArticleCase reports in ophthalmology
An Unexpected Response of Orbital Retinoblastoma to Inconsistent Systemic Chemotherapy Alone.
Article in Case reports in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Orbital Fungating Mass as a Rare Manifestation of Retinoblastoma: A Case Study in Palliative Care.The American journal of case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A 16-month-old girl presented with bilateral germline retinoblastoma, with advanced retinoblastoma in the right eye and severe orbital retinoblastoma in the left eye. Patients typically receive treatment with the multimodal protocol consisting of chemotherapy, surgery, and radiotherapy, which has improved survival. Case Presentation: Our patient elected for medical management with systemic chemotherapy instead of enucleation or exenteration. She received three blocks systemic chemotherapy consisting of vincristine sulfate, etoposide phosphate, and carboplatin, with irregular intervals between blocks over 3 years, due to poor compliance. Following chemotherapy, she had tumor regression in both eyes and no signs of active disease 13 years later. Conclusion: This case represents an interesting favorable outcome of orbital retinoblastoma management with systemic chemotherapy alone despite inconsistency versus conventional multimodal protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.